PubRank

Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma

Clinical Trial ID NCT02303899

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02303899

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003 11.22
2 Targeted cancer therapy. Nature 2004 7.81
3 Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004 3.72
4 Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001 2.79
5 Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002 2.70
6 Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 2003 1.84
7 Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006 1.66
8 Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. Eur J Cancer 2006 1.55
9 Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett 2005 1.53
10 Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol 2001 1.28
11 STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003 1.27
12 Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005 1.12
13 Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2007 1.09
14 Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008 1.09
15 Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction. Clin Exp Metastasis 1998 1.08
16 Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res 2008 1.06
17 FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene 2006 1.04
18 Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 2009 0.94
19 Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors. Clin Cancer Res 2007 0.93
20 Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol 2001 0.92
21 Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2006 0.91
22 Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 2007 0.88
23 Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells. J Neurosurg 2002 0.88
24 Regulation of differential expression of platelet-derived growth factor alpha- and beta-receptor mRNA in normal and malignant human mesothelial cell lines. Biochim Biophys Acta 1996 0.83
25 Differential expression of platelet derived growth factor-beta in malignant mesothelioma: a clue to future therapies? Surg Oncol 1993 0.81
26 Biological and immunological aspects of malignant mesothelioma. Eur Respir J 1995 0.80
Next 100